Neurotransmitter interactions in schizophrenia - Therapeutic implications

Biological Psychiatry

Volumn 46, Issue 10, 1999, Pages 1388-1395

  Carlsson, Arvid ^a   Waters, Nicholas ^a   Carlsson, Maria L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Antipsychotics; Dopamine; Glutamate; Neurocircuits; Neurotransmitters; Schizophrenia; Seroton in

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; 4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 5 HYDROXYTRYPTOPHAN; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPHETAMINE; CLOZAPINE; DIZOCILPINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; EGLUMETAD; ERGOLINE DERIVATIVE; GLUTAMIC ACID; HALOPERIDOL; KETAMINE; LYSERGIDE; N (2 CHLORO 6 METHYLERGOLIN 8ALPHA YL)PIVALAMIDE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PHENCYCLIDINE; SEROTONIN; SEROTONIN 2 ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; GABAERGIC SYSTEM; HUMAN; NEGATIVE SYNDROME; NEUROTRANSMISSION; PRIORITY JOURNAL; RECEPTOR BLOCKING; SCHIZOPHRENIA; THALAMUS;

EID: 0032754397     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00117-1     Document Type: Review

References (30)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Laruelle M., et al. Increased striatal dopamine transmission in schizophrenia confirmation in a second cohort . Am J Psychiatry. 155:1998;761-767.
2. 11C]5-hydroxytryptophan in major depression a positron emission tomography study on patients and healthy volunteers . Acta Psychiatr Scand. 83:1991;449-455.
3. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits neural substrates of parallel processing . Trends Neurosci. 13:1990;266-271.
4. Breier A., Su T.-P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations evidence from a novel positron emission tomography method . Proc Natl Acad Sci USA. 94:1997;2569-2574.
5. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-186.
6. Carlsson A. The dopamine theory revisited. Hirsch S.R., Weinberger D.R. Schizophrenia. 1995;379-400 Blackwell Science, Oxford.
7. 2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse - implications for psychosis. J Neural Transm. 100:1995;225-237.
8. Carlsson M.L., Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm. 75:1989;221-226.
9. Carlsson M.L., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
10. Carlsson L.M., Svensson A. Interfering with glutamatergic neurotransmission by means of MK-801 administration discloses the locomotor stimulatory potential of other transmitter systems in rats and mice. Pharmacol Biochem Behav. 36:1990;45-50.
11. 2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice. J Neural Transm. 106:1999;123-129.
12. Dao-Costellana M.-H., Paillère-Martinot M.-L., Hantraye P., Attar-Lévy D., Rémy P., Crouzel C., et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res. 23:1997;167-174.
13. Garland Bunney B., Bunney W.E., Carlsson A. Schizophrenia and glutamate. Bloom F.E., Kupfer D.J. Psychopharmacology The Fourth Generation of Progress . 1995;1203-1214 Raven Press, New York.
14. Gellman R.L., Aghajanian G.K. IPSPs in pyramidal cells in piriform cortex evoked by monoamine excitation of interneurons demonstrate a convergence of inputs. Soc Neurosci Abstr. 17:1991;989.
15. Hansson L.O., Waters N., Winblad B., Gottfries C.-G., Carlsson A. Evidence for biochemical heterogeneity in schizophrenia a multivariate study of monoaminergic indices in human post-mortal brain tissue . J Neural Transm. 98:1994;217-235.
16. 2 autoreceptor ligands. Modeling of dopamine synthesis and release in vivo by means of partial least squares regression. J Med Chem. 38:1995;3121-3131.
17. 2-dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry. 51:1994;116-123.
18. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmüller. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett. 20:1980;379-382.
19. Lahti A.C., Weiler M.A., Corey P.K., Lahti R.A., Carlsson A., Tamminga C.A. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia. Biol Psychiatry. 43:1998;2-11.
20. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, et al (1996): Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93:9235-9240.
21. 11-labeled L-dopa and positron emission tomography (PET). Abstract, 36th Annual ACNP Meeting, December 8-12, 1997, p 290.
22. Lodge D. Modulation of N-methylaspartate receptor channel complexes. Drugs Today. 25:1989;395-411.
23. 2A receptor antagonism is dependent on increased serotonergic tone . J Neural Transm. 105:1998;365-396.
24. Miller D.W., Abercrombie E.D. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res Bull. 40:1996;57-62.
25. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 281:1998;1349-1352.
26. 2A receptors in antipsychotic activity. Life Sci. 56:1995;2209-2222.
27. Sonesson C., Lin C.-H., Hansson L., Waters N., Svensson K., Carlsson A., et al. Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists synthesis and structure-activity relationships . J Med Chem. 37:1994;2735-2753.
28. Svensson K., Hjorth S., Clark D., Carlsson A., Wikström H., Andersson B., et al. (+)-UH 232 and (+)-UH 242 Novel stereoselective DA receptor antagonists with preferential action on autoreceptors . J Neural Transm. 65:1986;1-27.
29. Tamminga C.A., Crayton J.C., Chase T.N. Muscimol GABA agonist therapy in schizophrenia . Am J Psychiatry. 135:1978;746-748.
30. Waters N., Lundgren C., Hansson L.O., Carlsson M.L. Concurrent locomotor stimulation and decrease in dopamine in rats and mice after treatment with the competitive NMDA receptor antagonists D-CPPene and CGS 19755. J Neural Transm. 103:1996;117-129.